(Q43000773)

English

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis

scientific article published in July 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

author name string

B Meyer-Wyss

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

P Rich

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hp Egger

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

B Helbling

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

B Müllhaupt

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

C Rammert

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

J-J Gonvers

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

C Oneta

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

D Criblez

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

L Rossi

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

J Borovicka

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

C Meyenberger

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

M Arn

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

E L Renner

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Swiss Association for the Study of the Liver (SASL)

15

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

457-465

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00709.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2005.00709.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43000773&oldid=1976337844"